Association between prostate-specific antigen and leptin, adiponectin, HbA1c or C-peptide among African-American and Caucasian men

Fowke, Jay H.; Matthews, Charles; Buchowski, Maciej S.; Signorello, Lisa B.; Chang, Sam S.; Cookson, Michael S.; Blot, William J.

doi:10.1038/sj.pcan.4501022

Cited by 32 publications

(41 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As our study was the first to investigate the diabetic medication in detail, we could further show the largest reduction for men using insulin, whereas oral diabetic medication was associated with a lower PSA reduction and whereas diabetic men with no medication tended to have similar PSA levels compared with nondiabetic men. The hypothesis that more severe forms of diabetes might be associated with a lower PSA level was further supported by the inverse association of HbA1c measurements with PSA levels in our study, a result that was also seen by Fowke et al (18) in Caucasian men. In contrast, Fukui et al (16) found no association between PSA levels and either Hba1c or medication in Japanese men.…”

Section: Discussionsupporting

confidence: 78%

Association of Diabetes and Body Mass Index with Levels of Prostate-Specific Antigen: Implications for Correction of Prostate-Specific Antigen Cutoff Values?

Müller

Raum

Rothenbacher

et al. 2009

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: In a recent study, an inverse association between diabetes and prostate-specific antigen (PSA) levels was observed, and several studies reported lower PSA levels in groups with higher body mass index. However, all of the studies were conducted in populations with intensive PSA screening and the role of diabetes severity, duration, and therapy are yet to be explored. Methods: Associations of diabetes duration and treatment, hemoglobin A1c, and BMI with PSA levels were assessed among 778 men ages 50 to 74 years, randomly chosen from the 2000 to 2002 baseline recruitment of a large population-based cohort study in Germany (prevalence of diabetes, 17%), using linear regression analyses.

show abstract

Section: Discussionsupporting

confidence: 78%

Association of Diabetes and Body Mass Index with Levels of Prostate-Specific Antigen: Implications for Correction of Prostate-Specific Antigen Cutoff Values?

Müller

Raum

Rothenbacher

et al. 2009

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…6 In a cross-sectional sample of the Southern Community Cohort Study aged 40-78 years, Fowke et al reported decreasing mean PSA with increasing HbA1c quartiles (p trend =0.005) among Caucasian men. 7 In contrast to these cross-sectional studies and our current report, longitudinal observations in a Japanese hospital cohort found increases in HbA1c and PSA to be concordant (5.7% increase per 1-unit HbA1c change, p<0.001). 27 However, when the data were analyzed in a cross-sectional manner, the authors reported small non-significant inverse relationships between HbA1c and PSA.…”

Section: Discussioncontrasting

confidence: 51%

“…Specifically, previous studies have demonstrated lower PSA in men with type 2 diabetes mellitus (T2DM) and inverse associations between poor glycemic control, as assessed by hemoglobin A1c (HbA1c), and PSA. [6][7][8][9] There are several possible explanations why PSA may be lower among men with T2DM than among men without T2DM, including greater obesity and more frequent use of medications used to treat dyslipidemia and hypertension. Men with higher BMI have lower mean total PSA than men with lower BMIs, [10][11][12] possibly due to hemodilution from increased plasma volume in larger men, 13 or lower androgen levels that characterize more obese and insulin resistant adult males.…”

Section: Introductionmentioning

confidence: 99%

78 Poor Glycemic Control Is Associated With Reduced Prostate-Specific Antigen Concentrations in Men With Type 1 Diabetes

Sarma

Hotaling

Cleary³

et al. 2012

Journal of Urology

View full text Add to dashboard Cite

PURPOSE-Previous studies have demonstrated lower prostate-specific antigen (PSA) concentrations in men with type 2 diabetes (T2DM), paralleling the reported lower prevalence of prostate cancer among diabetic men. Data on PSA in men with type 1 diabetes (T1DM), in whom insulin and obesity profiles differ from those in T2DM, are lacking. The objective of this study was to examine the relationship between long-term glycemic control and PSA in men with T1DM. MATERIALS & METHODS-TotalPSA was measured at one time in 639 men in the Epidemiology of Diabetes Interventions and Complications (EDIC) study, the observational follow up of participants in the Diabetes Control and Complications Trial (DCCT). The relationship between DCCT/EDIC weighted mean HbA1c and log PSA was assessed using linear regression modeling after adjusting for age, body mass index (BMI), total testosterone, statin and thiazide medication use, diabetes duration, and DCCT randomization arm and cohort. RESULTS-The subjects had a median age of 52 years, BMI of 28.4 kg/m 2 and DCCT/EDIC time weighted HbA1c of 7.9%. Total median (interquartile range) for PSA levels was 0.64 (0.43, 1.05). PSA levels increased significantly with age (p<0.0001) and with lower time weighted HbA1c (p<0.0001). Each 10% increase in HbA1c was accompanied by an 11% reduction in PSA (p=0.0001). CONCLUSIONS-PSA levels decrease as HbA1c increases in men with T1DM. This relationship is independent of age, BMI, androgen levels, medication use and measures of diabetes severity, which suggest that factors related to glycemia may be directly affecting PSA levels. HHS Public Access

show abstract

“…Most studies reported that men with MS had lower PSA than men without MS. [1][2][3][4] Data from the National Health and Nutrition Examination Survey in [2001][2002][2003][2004] showed that the mean PSA of men with MS is slightly lower than of men without MS (0.98 ng/mL vs 0.87 ng/mL), although it was not statistical significant (P = 0.20).…”

Section: Discussionmentioning

confidence: 99%

“…However, most of the previous studies that examined the relationship of MS and PSA did not adjust prostate volume. [1][2][3][4][5][6] Interestingly, the PSA of men with MS was not higher than that without MS in those studies. mass (serum PSA 9 plasma volume) was used to adjust the plasma volume, and there were no significant differences of PSA mass between men with MS and without MS.…”

Section: Introductionmentioning

confidence: 92%

Prostate‐specific antigen lowering effect of metabolic syndrome is influenced by prostate volume

et al. 2016

View full text Add to dashboard Cite

Abbreviations & Acronyms ALT = alanine transaminase AST = aspartate aminotransferase BMI = body mass index BPH = benign prostatic hyperplasia BSA = body surface area Cr = serum creatinine DBP = diastolic blood pressure FBG = fasting blood glucose HDL = high-density lipoprotein LUTS = lower urinary tract symptom MS = metabolic syndrome PSA = prostate-specific antigen SBP = systolic blood pressure TRUS = transrectal ultrasonography Objectives: To investigate the influence of metabolic syndrome on prostate-specific antigen levels by considering prostate volume and plasma volume. Methods: We retrospectively analyzed 4111 men who underwent routine check-ups including prostate-specific antigen and transrectal ultrasonography. The definition of metabolic syndrome was based on the modified Adult Treatment Panel III criteria. Prostate-specific antigen mass density (prostate-specific antigen 9 plasma volume / prostate volume) was calculated for adjusting plasma volume and prostate volume. We compared prostate-specific antigen and prostate-specific antigen mass density levels of participants with metabolic syndrome (metabolic syndrome group, n = 1242) and without metabolic syndrome (non-prostate-specific antigen metabolic syndrome group, n = 2869). To evaluate the impact of metabolic syndrome on prostate-specific antigen, linear regression analysis for the natural logarithm of prostate-specific antigen was used. Results: Patients in the metabolic syndrome group had significantly older age (P < 0.001), larger prostate volume (P < 0.001), higher plasma volume (P < 0.001) and lower mean serum prostate-specific antigen (non-metabolic syndrome group vs metabolic syndrome group; 1.22 AE 0.91 vs 1.15 AE 0.76 ng/mL, P = 0.006). Prostate-specific antigen mass density in the metabolic syndrome group was still significantly lower than that in the metabolic syndrome group (0.124 AE 0.084 vs 0.115 AE 0.071 lg/mL, P = 0.001). After adjusting for age, prostate volume and plasma volume using linear regression model, the presence of metabolic syndrome was a significant independent factor for lower prostatespecific antigen (prostate-specific antigen decrease by 4.1%, P = 0.046). Conclusions: Prostate-specific antigen levels in patients with metabolic syndrome seem to be lower, and this finding might be affected by the prostate volume.

show abstract

Association between prostate-specific antigen and leptin, adiponectin, HbA1c or C-peptide among African-American and Caucasian men

Cited by 32 publications

References 55 publications

Association of Diabetes and Body Mass Index with Levels of Prostate-Specific Antigen: Implications for Correction of Prostate-Specific Antigen Cutoff Values?

Association of Diabetes and Body Mass Index with Levels of Prostate-Specific Antigen: Implications for Correction of Prostate-Specific Antigen Cutoff Values?

78 Poor Glycemic Control Is Associated With Reduced Prostate-Specific Antigen Concentrations in Men With Type 1 Diabetes

Prostate‐specific antigen lowering effect of metabolic syndrome is influenced by prostate volume

Contact Info

Product

Resources

About